🇺🇸 Gemcitabine + Rituximab in United States
15 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 15
Most-reported reactions
- Cytokine Release Syndrome — 3 reports (20%)
- Death — 3 reports (20%)
- Immune Effector Cell-Associated Neurotoxicity Syndrome — 2 reports (13.33%)
- Aplastic Anaemia — 1 report (6.67%)
- B-Cell Lymphoma Recurrent — 1 report (6.67%)
- Bacterial Sepsis — 1 report (6.67%)
- Clostridium Difficile Infection — 1 report (6.67%)
- Composite Lymphoma — 1 report (6.67%)
- Confusional State — 1 report (6.67%)
- Constipation — 1 report (6.67%)
Other Oncology approved in United States
Frequently asked questions
Is Gemcitabine + Rituximab approved in United States?
Gemcitabine + Rituximab does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Gemcitabine + Rituximab in United States?
CTI BioPharma is the originator. The local marketing authorisation holder may differ — check the official source linked above.